Regenxbio (RGNX) EBT (2014 - 2026)

Regenxbio's EBT history runs 12 years deep, the most recent figure standing at $89.8 million for Q4 2025.

• In Q4 2025, EBT rose 234.83% year-over-year to $89.8 million; the TTM figure through Dec 2025 stood at -$43.0 million (up 83.11% YoY), while the FY2025 annual figure was -$535.6 million, down 135.82% from the prior year.
• EBT for Q4 2025 stood at $89.8 million, up from -$65.5 million in the prior quarter.
• The five-year high for EBT was $307.4 million in Q4 2021, with the low at -$76.8 million in Q1 2022.
• The 5-year median for EBT is -$62.4 million (2023), against an average of -$21.0 million.
• Peak annual rise in EBT reached 859.11% in 2021, while the deepest fall reached 764.6% in 2021.
• Regenxbio's EBT stood at $307.4 million in 2021, then fell by 28.32% to $220.4 million in 2022, then sank by 128.58% to -$63.0 million in 2023, then retreated by 5.8% to -$66.6 million in 2024, then jumped by 234.83% to $89.8 million in 2025.
• Business Quant data shows RGNX's EBT at $89.8 million in Q4 2025, -$65.5 million in Q3 2025, and -$70.9 million in Q2 2025.